NCT05234775View on ClinicalTrials.gov

Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product

PHASE3CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 28, 2022

Primary Completion Date

June 30, 2022

Study Completion Date

July 11, 2022

Conditions
Hypercholesterolemia
Interventions
DRUG

lerodalcibep

300 mg of each drug given SC as single dose

Trial Locations (1)

45227

Metabolic & Atherosclerosis Research Center (MARC), Cincinnati

Sponsors

Collaborators (1)

Medpace, Inc.
All Listed Sponsors
collaborator

Medpace, Inc.

INDUSTRY

lead

LIB Therapeutics LLC

INDUSTRY

NCT05234775 - Cross-Over Study to Compare the Pharmacokinetics and Pharmacodynamics of LIB003 Process 1 and Process 2 Drug Product | Biotech Hunter | Biotech Hunter